This publication has and will continue to argue that processes like the HTA review simply cannot deliver the reform people expect because it's not an enabling policy framework. It will deliver targeted adjustments to the access barrier. Is that what stakeholders want?
It's important to understand that health technology assessment is not an enabler
April 24, 2025 Latest NewsBioPharmaComment
Latest Video
New Stories
-
US launches investigation into pharmaceutical pricing with potential broad implications
June 23, 2026 - - Latest News -
Access delays in cancer medicines are costing Australia productivity, livelihoods, and lives
June 23, 2026 - - Latest News -
If we're incapable of delivering meaningful change, we should hope the US intervenes
June 23, 2026 - - Latest News -
'AUScelerate' emerges as new name for MTPConnect ahead of BIO 2026
June 22, 2026 - - Australian Biotech -
CSL executive Elizabeth Rex joins AusBiotech board as observer
June 22, 2026 - - Latest News -
It seems that one critical stakeholder group is missing in this website design
June 22, 2026 - - Latest News -
May 2026 delivers paediatric dosing flexibility, vaccine decisions, and policy updates
June 22, 2026 - - Latest News


